- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05278715
Modified CV Regimen in Optic Pathway Glioma
Clinical Study of Modified Carboplatin/Vincristine Chemotherapy Regimen for Visual Function Protection in Children With Optic Pathway Gliomas
Optic pathway glioma (OPG) can result in visual deterioration. Symptomatic patients often report deficits in visual acuity (VA), visual field, visual-evoked potentials (VEPs), strabismus, proptosis, disc swelling, and other visual/neurological problems. VA itself remains one of the most important outcome measures for OPG patients, with various studies showing strong ties of VA level to overall quality of life and well-being . Maintenance of favorable VA and vision outcomes is of paramount importance in the management of OPG. In terms of management of OPG, surgery and radiotherapy are used on a more limited basis because of location of the tumors and risk of secondary tumors, respectively. Tumor stabilization often prioritized, and chemotherapy is considered ideal for tumor stabilization in OPG, but vision is not always retained and may worsen in some cases, partially due to low radiographic efficacy and long time interval to response of the current chemotherapy regimen.
In the prior study, the investigators modified the traditional carboplatin combined with vincristine regimen by increasing the dose of carboplatin and combining with an anti-angiogenic drug. Of the 15 OPG patients, objective response rate was 80% and the time to response was only 3.3 months. 8 (53%) patients experienced an improvement in visual acuity during therapy and 6 (40%) were stable, which was higher than the historical studies.
This study was launched to further verify the clinical efficacy of the modified regimen and its effect on visual acuity improvement.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jun-ping Zhang
- Phone Number: 86-010-62856783
- Email: doczhjp@hotmail.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Capital Medical University Sanbo Brain Hospital
-
Contact:
- Jun-ping Zhang
- Phone Number: 86-010-62856783
- Email: doczhjp@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 3months and ≤21years;
- Patients with optic pathway gliomas diagnosed by histopathology or characteristic brain MRI and clinical features;
- Measurable lesions, surgical resection degree < 95% or postoperative residual tumor ≥1.5cm^2;
- KPS score ≥50 (age >12 years) or Lansky score ≥50 (age ≤12 years);
- Clinical symptoms such as decreased visual acuity, visual field defect, optic disc edema, exophthalmia, increased intracranial pressure, diencephalic syndrome, etc;
- No dysfunction of major organs.
Exclusion Criteria:
- MRI examination is not available.
- Failing to comply with the visual examination.
- H3K27 mutations, even histopathological grade 1/2.
- Receiving any other investigational agent.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in this study.
- Patients who have received organ transplants.
- Patients infected with HIV or treponema pallidum.
- Suffering from serious cardiovascular disease;T wave inversion or elevation or ST segment changes.
- Patients who had coagulation disorder and were being treated with thrombolytic or anticoagulant drugs. Patients with significant clinical bleeding symptoms or clear bleeding tendency occurred within 3 months before enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, gastrointestinal perforation, baseline fecal occult blood ++ or above, intratumoral or intracranial bleeding, or vasculitis, etc. Arteriovenous thrombosis events (such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage and cerebral infarction), deep vein thrombosis and pulmonary embolism) occurred within 6 months before enrollment.
- Pregnant or breastfeeding.
- Other conditions considered inappropriate by the researcher for inclusion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: optic pathway glioma
|
Dose of carboplatin is adjusted for age (over 1 year old, full dose, 220 mg/m^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent).
Dose of vincristine is adjusted for age (over 1 year old, full dose, 1.5 mg/m^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent).
Maximum dose is 2 mg.
Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VA improvement rate
Time Frame: up to 3 years
|
Percentage of visual acuity improvement
|
up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
time to VA improvement
Time Frame: up to 3 years
|
Time interval from the beginning of chemotherapy to VA improvement
|
up to 3 years
|
objective response rate
Time Frame: up to 3 years
|
the percentage of patients who achieved confirmed complete response, partial response or minor response
|
up to 3 years
|
median time to response
Time Frame: up to 3 years
|
Time interval from the beginning of chemotherapy to achieving complete response, partial response or minor response
|
up to 3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Eye Diseases
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Nervous System Neoplasms
- Optic Nerve Diseases
- Cranial Nerve Diseases
- Peripheral Nervous System Neoplasms
- Cranial Nerve Neoplasms
- Optic Nerve Neoplasms
- Glioma
- Optic Nerve Glioma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Carboplatin
- Vincristine
- Endostatins
Other Study ID Numbers
- 首发-2022-2-8012
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Optic Glioma
-
Benedetto FalsiniRecruitingOptic Pathway GliomaItaly
-
Washington University School of MedicineWithdrawnAstrocytoma | Ependymoma | Oligodendroglioma | Brainstem Glioma | Mixed Glioma | Optic Nerve Glioma
-
Washington University School of MedicineRecruitingGlioma | Glioblastoma | Astrocytoma | Anaplastic Astrocytoma | Oligodendroglioma | Pilocytic Astrocytoma | Mixed Oligoastrocytoma | Mixed Glioma | Optic GliomaUnited States
-
Burzynski Research InstituteCompletedVisual Pathway GliomaUnited States
-
Burzynski Research InstituteWithdrawnOptic Nerve Glioma
-
Emory UniversityCURE Childhood Cancer, Inc.CompletedJuvenile Pilocytic Astrocytomas | Optic Pathway GliomasUnited States
-
Julie KrystalJanssen PharmaceuticalsRecruitingGlioblastoma Multiforme | Gliosarcoma | Anaplastic Astrocytoma | Pleomorphic Xanthoastrocytoma | Pilocytic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Low-grade Glioma | DIPG | Brainstem Glioma | Optic Nerve Glioma | Pilomyxoid Astrocytoma | Glioma, AstrocyticUnited States
-
UNC Lineberger Comprehensive Cancer CenterCompletedOptic Glioma | Plexiform Neurofibroma | Neurofibromatosis-1United States
-
National Cancer Institute (NCI)Active, not recruitingLow Grade Glioma | Recurrent Visual Pathway Glioma | Refractory Visual Pathway Glioma | Recurrent Childhood Pilocytic Astrocytoma | Recurrent Neurofibromatosis Type 1 | Refractory Neurofibromatosis Type 1United States
-
Rigshospitalet, DenmarkUniversity of Colorado, Denver; King's College Hospital NHS Trust; Odense University... and other collaboratorsRecruitingNon-arteritic Ischemic Optic Neuropathy | Optic Disk DrusenDenmark, United Kingdom, United States, Australia, Canada, France, Iran, Islamic Republic of, Israel, New Zealand
Clinical Trials on Carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Samyang Biopharmaceuticals CorporationCompleted
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedBrain and Central Nervous System TumorsUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Eli Lilly and CompanyCompletedLung NeoplasmsUnited States
-
MEI Pharma, Inc.CompletedPeritoneal Neoplasms | Ovarian Cancer | Fallopian Tube CancerUnited States, Spain, Belgium, United Kingdom, Australia, Italy, Poland